Literature DB >> 22941513

Immune pathogenesis and treatment of multifocal motor neuropathy.

Lotte Vlam1, Leonard H van den Berg, Elisabeth A Cats, Sanne Piepers, W-Ludo van der Pol.   

Abstract

Multifocal motor neuropathy (MMN) is a rare, probably immune-mediated chronic disorder characterized by asymmetric distal limb weakness and conduction block. The exact pathogenesis of MMN is still unclear, but IgM anti-GM1 antibodies, which can be detected in sera from approximately half of all MMN patients, are thought to play an important role. Treatment with intravenous immunoglobulin (IVIG) is effective in the vast majority of patients, but, despite IVIG maintenance treatment, many patients experience a slowly progressive decline in muscle strength. In this review we will summarize the results from studies on pathogenesis. We will discuss current treatment strategies of MMN and how insight into MMN pathogenesis may translate into novel therapies in the future.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941513     DOI: 10.1007/s10875-012-9779-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  25 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

2.  Multifocal motor neuropathy: serum IgM binding to a GM1 ganglioside-containing lipid mixture but not to GM1 alone.

Authors:  A Pestronk; R Choksi; G Blume; G Lopate
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

3.  Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy.

Authors:  N A Sutedja; H G Otten; E A Cats; S Piepers; J H Veldink; W L van der Pol; L H van den Berg
Journal:  Neurology       Date:  2010-03-09       Impact factor: 9.910

Review 4.  Immunotherapy of multifocal motor neuropathy.

Authors:  Filip Eftimov; Ivo N Van Schaik
Journal:  Expert Opin Biol Ther       Date:  2011-03       Impact factor: 4.388

5.  Conduction block in acute motor axonal neuropathy.

Authors:  Norito Kokubun; Momoka Nishibayashi; Antonino Uncini; Masaaki Odaka; Koichi Hirata; Nobuhiro Yuki
Journal:  Brain       Date:  2010-09-20       Impact factor: 13.501

6.  Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.

Authors:  T Harbo; H Andersen; A Hess; K Hansen; S H Sindrup; J Jakobsen
Journal:  Eur J Neurol       Date:  2009-02-19       Impact factor: 6.089

7.  Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain-Barré syndrome.

Authors:  Vongsavanh Phongsisay; Keiichiro Susuki; Kenjiro Matsuno; Takuyu Yamahashi; Saori Okamoto; Kei Funakoshi; Koichi Hirata; Motoo Shinoda; Nobuhiro Yuki
Journal:  J Neuroimmunol       Date:  2008-10-29       Impact factor: 3.478

8.  Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

Authors:  Sanne Piepers; Renske Van den Berg-Vos; W-Ludo Van der Pol; Hessel Franssen; John Wokke; Leonard Van den Berg
Journal:  Brain       Date:  2007-07-10       Impact factor: 13.501

Review 9.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

10.  Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members.

Authors:  Elisabeth A Cats; Anne Suzanne Bertens; Jan H Veldink; Leonard H van den Berg; W Ludo van der Pol
Journal:  J Neurol       Date:  2011-11-23       Impact factor: 4.849

View more
  6 in total

Review 1.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

2.  Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.

Authors:  Xianzhen Hu; V Michael Holers; Joshua M Thurman; Trent R Schoeb; Theresa N Ramos; Scott R Barnum
Journal:  Mol Immunol       Date:  2013-01-20       Impact factor: 4.407

3.  Complement activity is associated with disease severity in multifocal motor neuropathy.

Authors:  Lotte Vlam; Elisabeth A Cats; Oliver Harschnitz; Marc D Jansen; Sanne Piepers; Jan Herman Veldink; Hessel Franssen; Abraham C J Stork; Erik Heezius; Suzan H M Rooijakkers; Bjorn L Herpers; Jos A van Strijp; Leonard H van den Berg; W Ludo van der Pol
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-06-25

Review 4.  Human immune globulin infusion in the management of multifocal motor neuropathy.

Authors:  Elizabeth Jovanovich; Chafic Karam
Journal:  Degener Neurol Neuromuscul Dis       Date:  2015-12-22

5.  Contactin-1 and Neurofascin-155/-186 Are Not Targets of Auto-Antibodies in Multifocal Motor Neuropathy.

Authors:  Kathrin Doppler; Luise Appeltshauser; Heidrun H Krämer; Judy King Man Ng; Edgar Meinl; Carmen Villmann; Peter Brophy; Sulayman D Dib-Hajj; Stephen G Waxman; Andreas Weishaupt; Claudia Sommer
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

Review 6.  Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.

Authors:  Victoria H Lawson; W David Arnold
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-05       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.